Provided are CD96-modified and TIGIT-modified NK-92 cells comprising one or more alterations that inhibit expression of CD96 and/or TIGIT. Also provided are methods of generating such modified NK-92 cells and methods of treating a subject having or suspected of having a cancer using the modified NK-92 cells.